Catherine J Dargan

Catherine Dargan is co-chair of our mergers & acquisitions practice group. She has broad experience in mergers and acquisitions, both public and private, and strategic partnering arrangements. In addition to structuring and negotiating transactions, she assists clients with corporate governance issues, compliance matters, financing agreements, employment and consulting arrangements, and other matters. Ms. Dargan also regularly advises clients on a variety of commercial agreements relating to manufacturing, supply, and distribution of core products. She represents clients in a variety of industries including life sciences, consumer products, technology, government contractors, communications and media; sports and entertainment; pharmaceutical, equipment, and food product manufacturing; and consulting and advisory services. REPRESENTATIVE MATTERS Represented AstraZeneca in its: acquisition of Ardea Biosciences (NASDAQ: RDEA) for $1.26 billion; and approximately $3.5 billion strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals, including assistance in structuring agreements for the acquisition and operation of Amylin’s diabetes business by AZ and BMS. Represented Boehringer Ingelheim in its acquisition of certain animal health products divested in connection with the Pfizer-Wyeth merger. Advised Salix Pharmaceuticals in its $300 million acquisition of Oceana Therapeutics, Inc. Represented Takeda in its acquisition of Intellikine, Inc. for $190 million upfront and up to $120 million in additional potential clinical development milestone payments. Represented Abbott Laboratories in its: acquisition of Evalve, Inc., a medical device developer, by Abbott Vascular for up to $410 million; and $3.7 billion acquisition of Kos Pharmaceuticals, Inc. (NASDAQ: KOSP). Advised Eli Lilly in its: acquisition of SGX Pharmaceuticals, Inc. (NASDAQ: SGXP), a San Diego-based biotechnology company; and divestiture of its Tippecanoe manufacturing facility to Evonik Industries. The Procter & Gamble Company in its 50/50 joint venture with Inverness Medical Innovations, Inc. for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products in a transaction valued at $650 million. More Representative Matters HONORS AND RANKINGS LMG Life Sciences, “Life Science Star” (2012) Legal 500 US, Mergers & Acquisitions (2012) PRO BONO Represented a non-profit, non-partisan policy organization dedicated to engaging young adults in the political process. Advised a non-profit in various consulting and services arrangements. MEMBERSHIPS AND AFFILIATIONS Law360, 2012 Mergers & Acquisitions Editorial Advisory Board PUBLICATIONS AND SPEECHES "Drafting Corporate Agreements — Letters of Intent, Confidentiality and Standstill Agreements," Faculty Member, Practising Law Institute (2011-2012) "Structuring and Negotiating Earn-Outs," Faculty Member, Seminar on Acquiring or Selling the Privately Held Company 2012, Practising Law Institute (2012)